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Abstract Sepsis presents a major health care problem and
remainsoneoftheleadingcausesofdeathwithintheintensive
care unit (ICU). Therapeutic approaches against severe sepsis
and septic shock focus on early identification. Adequate
source control, administration of antibiotics, preload optimi-
zation by fluid resuscitation and further hemodynamic
stabilisation using vasopressors whenever appropriate are
consideredpivotal withinthe early—golden—hours ofsepsis.
However, organ dysfunction develops frequently in and
represents a significant comorbidity of sepsis. A considerable
amount of patients with sepsis will show signs of severe
muscle wasting and/or ICU-acquired weakness (ICUAW),
which describes a frequently observed complication in
critically ill patients and refers to clinically weak ICU patients
in whom there is no plausible aetiology other than critical
illness. Some authors consider ICUAW as neuromuscular
organ failure, caused by dysfunction of the motor unit, which
consists of peripheral nerve, neuromuscular junction and
skeletal muscle fibre. Electrophysiologic and/or biopsy
studiesfacilitatefurthersubclassificationofICUAWascritical
illness myopathy, critical illness polyneuropathy or critical
illness myoneuropathy, their combination. ICUAW may
protract weaning from mechanical ventilation and impede
rehabilitation measures, resulting in increased morbidity and
mortality. This review provides an insight on the available
literature on sepsis-mediated muscle wasting, ICUAW and
their potential pathomechanisms.
Keywords ICU-acquired weakness.Critical illness
myopathy.Systemic inflammation.Immunity.Multiple
organ failure.CIP/CIM
1 Sepsis
1.1 Epidemiology and definition of sepsis
Sepsis is a leading cause of death in intensive care units
(ICU) [1–3]. In order to establish consensus definitions, the
terms systemic inflammatory response syndrome (SIRS),
sepsis, severe sepsis and septic shock have been proposed
[4–7]. These terms define gradual stages of disease severity
that correlate with mortality. Whereas SIRS defines a rather
unspecific inflammatory host response due to both infec-
tious and non-infectious origin, severe sepsis refers to a
proven systemic infection associated with acute organ
dysfunction. Criteria of septic shock are met once additional
volume-refractory hemodynamic failure occurs [4, 5].
Recently, there has been great effort in studying the
epidemiology of sepsis [2]. Data from the United States report
750,000 cases/year of severe sepsis [8] and an overall
mortality of 29% for 2001. A 9% annual increase of severe
sepsis incidence between 1977 and 2000 was reported [9].
Epidemiological trials from Germany indicate that 79,000
inhabitants (116/100,000) will suffer from sepsis each year
and an additional 75,000 inhabitants (110/100,000) will be
diagnosed with severe sepsis. Ninety-day mortality of severe
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year in Germany, sepsis remains a leading cause of death and
a considerable burden for health care systems [10–12].
1.2 Fundamental clinical and pathophysiological
considerations in sepsis
T r e a t m e n to fp a t i e n t sw i t hs e p s i ss h o u l db ei m p l e m e n t e d
according to international guidelines and recommendations,
e.g.,asproposedbythe SurvivingSepsisCampaign[4]. Early
identification and therapy initiation seem of pivotal impor-
tance and were shown to significantly improve patients’
prognoses. In general, guidelines for the treatment of severe
sepsis or septic shock aim to initiate early symptomatic organ
support therapies; e.g. early optimization of cardiac preload,
afterload and contractility in order to balance oxygen
delivery with oxygen demand influences survival rates in
sepsis [13]. Over the past years, several treatment approaches
have been associated with beneficial outcomes in large-scale,
mostlysingle-centre trials,including low-dose hydrocortisone
[14], glycemic control [15, 16] and recombinant activated
protein C [17]. Yet, these benefits could not be replicated by
confirmative studies [18–20].
Pathophysiologically, the first response to a severe
infection consists in the activation of antigen-presenting
immune cells. This occurs via pattern recognition receptors
[1, 21–23] and is accompanied by other immune mecha-
nisms such as cytokine liberation, endothelium and com-
plement activation, and release of oxygen radicals.
Cytokines (tumour-necrosis factor alpha (TNF-α), interleu-
kin (IL)-6 and IL-1) and complement factors (C3a and C5a)
may then act as key mediators during this stage of
inflammation [21]. Clinical signs of infection such as
leukocytosis, increased respiratory rate or acute organ
failure may then develop [1] and, as a protective measure,
the immune system coordinates an immunological and
endocrine counter-regulation which is mediated by up-
regulation of key anti-inflammatory cytokines (e.g. IL-10,
tumour-growth factor-ß) [7, 24–27]. This may lead to
prolonged hypo-inflammatory states (“immunoparalysis”)
[27], which have been linked to secondary/nosocomial
infection, prolonged ICU stay, chronic multiple organ
failure and an increased mortality [21–31]. Ongoing clinical
trials investigate measures of immunostimulation [28–30]
or removal of inhibitory factors [31] to reverse this
immunological condition.
Inflammation-mediated organ dysfunction represents a
detrimental comorbidity of sepsis. As sepsis is frequently
accompanied by short- and long-term affection of neuro-
muscular function, it has been postulated that the “motor
unit” presents another system affected by inflammation-
mediated multiple organ dysfunction: Sepsis is not only
associated with involuntary loss of muscle mass, which is
frequently referred to as muscle wasting, but also severe
neuromuscular dysfunction resulting in “ICU-acquired
weakness” (ICUAW). Patients with acute respiratory
distress syndrome show a particularly high incidence for
ICU-acquired weakness [32].
2 Sepsis-induced muscle wasting and ICUAW:
an imbalance in protein metabolism
William Osler first commented on the “rapid loss of flesh”
that occurs with severe sepsis in 1892 [33]. Today, this
phenomenon remains a frequent complication of critical
illness—particularly sepsis—and is often referred to as
muscle wasting. However, because sepsis led to a fairly
rapid death in Osler’s days, the primary focus was rather
survival than sepsis-associated long-term complications.
Yet, once ICU and artificial organ support therapies are
available, more patients survive the initial stages of
systemic inflammation/sepsis and critical care specialists
are increasingly confronted with profound muscle weak-
ness, which is often accompanied by difficulties in weaning
from respiratory support. Sepsis-induced multiple organ
failure has been identified as one of the primary risk factors
for this major and frequent complication of critical illness
[34]. As a confusing number of various terminologies
referred to similar or identical clinical presentations of this
neuromuscular disorder, a recent round table conference
held in 2009 proposed the mutual term “ICUAW” [35].
Whereas ICUAW is usually accompanied by muscle
wasting, muscle wasting does not necessarily lead to
neuromuscular dysfunction, since overall muscle strength
depends both on total muscle mass and force generating
capacity (force per cross-sectional area), which is affected in
ICUAW but not necessarily in muscle wasting syndromes
[36]( F i g .1).
2.1 Sepsis-associated muscle wasting
As mentioned above, muscle force capacity may remain
stable in muscle wasting syndromes [36]. Muscle wasting
can be triggered by other conditions than sepsis, including
disuse, denervation, fasting, cancer, cardiac failure and
renal dysfunction. As these conditions frequently coincide
with sepsis, systematic research of sepsis-specific muscle
wasting and ICUAW may be challenging in humans. This
seems especially the case as sepsis is often accompanied by
prolonged bedrest/immobilisation, application of sedatives,
acute or chronic organ dysfunction, malignancy as an
underlying disease, medication using glucocorticoids and
others.
An imbalance between muscle protein synthesis and
muscle protein degradation causing net loss of muscle mass
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atrophy in muscle wasting and may result from decreased
protein synthesis and/or increased protein degradation [36]
(Fig. 1).
2.2 Decreased muscle protein synthesis during sepsis
Even though studies on sepsis-induced muscle protein
degradation received more attention, animal models of
sepsis clearly indicate that sepsis also decreases protein
synthesis in skeletal muscles [37] and preferentially inhibits
myofibrillar and sarcoplasmatic protein synthesis within
fast twitch muscles [38].
One central mechanism is decreased protein transla-
tion by lower amounts of active translation initiation
factor complex eIF4E/eIF4G, possibly resulting from
decreased phosphorylation of eIF4G and mammalian
target of rapamycin (mTOR) [37]. Interestingly, mTOR
activation presents an important downstream target of
anabolic insulin/insulin like growth factor 1 (IGF-1)
signalling, which may be impaired in sepsis since
decreased insulin sensitivity presents a frequently ob-
served complication of sepsis [39–44]. Further indirect
evidence for contribution of impaired insulin signalling to
decreased protein synthesis comes from the observation
that the proinflammatory cytokines IL-6 and TNF-α have
been linked to both insulin resistance [45, 46]a n dm u s c l e
atrophy [47–50] and that local IGF-1 application prevents
sepsis-induced muscle atrophy [37], possibly by inhibition
of sepsis-induced increases of muscle atrogin-1 and the
proinflammatory cytokine IL-6 [51]. IL-1 may lead to
decreased protein synthesis as well, as an animal model of
abdominal sepsis showed cytokine-dependent decreases of
phosphorylated eIF4G that was primarily attributed to this
cytokine [52]. There is evidence that systemic cytokine
response in sepsis results in local amplification of
proinflammatory cytokines within muscle [36], possibly
aggravating decreased protein synthesis in skeletal muscle
during sepsis.
Nutritional aspects may contribute to decreased muscle
protein synthesis as well. Administration of the essential
branched chain amino acid leucine has been shown to
increase protein synthesis in rat skeletal muscles during
ageing, exercise or food-deprivation [53–56]. However,
under certain conditions including sepsis, the muscle may
be resistant to leucine-stimulated protein synthesis [37].
Although the exact mechanisms of sepsis-induced leucine
resistance remain to be elucidated, this phenomenon was
accompanied by an 80% reduction in the amount of active
eIF4E/eIF4G complex (besides other factors) and could be
completely reversed by the combination of TNF binding
protein and glucocorticoid receptor antagonist RU486 [57].
Exploring the underlying mechanism of sepsis-induced
resistance to leucine-stimulated protein synthesis may
contribute to a better understanding of the mechanisms
involved in sepsis-mediated reductions of active translation
initiation factor complexes, particularly the eIF4E/eIF4G
complex.
Fig. 1 Risk factors involved in
muscle wasting and ICUAW.
Both complications may overlap
in septic patients, yet they present
two distinct entities that should
not be used synonymously.
Whereas ICUAW is most likely
accompanied by muscle wasting,
muscle wasting is not necessarily
associated with ICUAW
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Data from studies in cultured cells, animals and humans
indicate an increase of sepsis-associated muscle protein
degradation by several mechanisms, including the ubiquitin
proteasome system (UPS) [58–61] and lysosomal systems
[50, 62–64]. Calcium-dependent non-lysosomal calpains
and pro-apoptotic pathways (caspases) have also been
associated with sepsis-induced muscle atrophy [66–68].It
has been postulated that caspases and calpains are respon-
sible for the cleavage of myofibrillar proteins preceding
their proteasomal degradation [65–67] and that cleavage is
necessary as the proteasome cannot degrade intact myofibril-
lar proteins. Protein degradation by proteasomal and/or
lysosomal systems may not be sepsis-specific as various other
conditions associated with muscle wasting share similar or
identical biochemical and transcriptional pathways.
During muscle wasting, defective insulin signalling may
not only be involved in decreased muscle protein synthesis,
but also in increased muscle proteolysis, since mTOR
inhibits autophagy-induced lysosomal proteolysis [68].
mTOR activation is regulated by phosphorylated Akt,
another key downstream effector of insulin signalling.
Phosphorylated Akt leads to phosphorylation of FOXO3
transcription factors, which results in FOXO3 translocation
from nucleus to cytoplasm and a thereby decreased
transcription of atrophy gene atrogin-1 [69].
E3 ubiqitin ligases, such as atrogin-1 and muscle ring
finger protein 1 (MuRF-1), represent substrate specific
enzymes involved in the UPS that prevent unselective
degradation by the proteasome and have been shown to be
markedly induced during experimental atrophic conditions
[70, 71]. Whereas myosin heavy chain and other myofi-
brillar proteins including myosin binding proteins were
identified as MuRF-1 substrates [72, 73], the only atrogin-1
substrates identified so far include MyoD and translation
initiation factor eIF3-f, which are both known to regulate
protein synthesis [74, 75]. It is therefore possible, that
atrogin-1 leads to muscle atrophy by selective breakdown
of key regulators of protein synthesis [76]. We emphasise
once more, that sepsis-mediated muscle wasting and ICU-
acquired weakness should not be used synonymously, as
ICUAW weakness represents its own entity, characterised
by additional factors.
3 ICUAW: clinical presentation, relevance, risk factors,
treatment options and subclassifications
3.1 General considerations on ICUAW
ICUAW presents a severe and frequent complication of
critical illness, confronting intensivists around the globe
with various difficulties. It is believed that ICUAW can
affect more than half of all ICU patients [77]. This
substantial neuromuscular complication of critical illness
is associated with increased rates of morbidity and
mortality, substantially affecting both short- and long-term
clinical outcomes in septic patients [78–85]. By causing
prolongation of ICU stay and rehabilitation, ICUAW leads
to an increased risk of secondary complications and a
higher demand on already limited resources of health care
systems. ICUAW is further associated with decreases in
health-related quality of life (HRQOL) which may be
impaired for years after ICU discharge [85, 86]. Modern
critical care must therefore no longer solely focus on
survival, but particularly consider HRQOL after ICU
discharge.
3.2 Clinical presentation and diagnostic limitations
of ICUAW
ICUAW refers to the bedside diagnosis of pronounced
weakness in ICU patients without plausible aetiology other
than critical illness [35]. Whereas the patients’ history
usually reveal exposure to ICUAW-associated risk factors
(see below), physical examination of awake and coopera-
tive patients with typical ICUAW shows symmetric
weakness and decreased tone. This primarily affects the
lower limbs but may extend to tetraplegia in more severe
cases, explaining its prior terminology of acute quadriplegic
myopathy. Muscles innervated by cranial nerves are
normally—yet not necessarily—spared, while respiratory
muscle function is frequently abnormal. Deep tendon
reflexes may be normal, decreased or absent [35]. When-
ever suspecting ICUAW, it is fundamental to rule out
prolonged neuromuscular blockade (involvement of cranial
nerve-innervated muscles), pre-existing neuromuscular dys-
function and other conditions as alternative causes. Cur-
rently, ICUAW is frequently evidenced by difficulties in
weaning from mechanical ventilation or unexpected prob-
lems with mobilisation. However, as weaning from respi-
ratory support may not be initiated for several days or even
weeks, it seems important to consider possible ICUAW
before development of its full extent in order to prevent or
at least attenuate underlying pathology by minimising risk
factor exposure [34].
After all, earlier detection of ICUAW is possible and can
be obtained by assessment of voluntary maximum strength
in ICU patients, either by hand dynamometry or according
to the Medical Research Council (MRC)-score [35]. The
MRC-score grades manually tested strength from 0 (no
movement observed) to 5 (muscle contracts normally
against full resistance) in three functional muscle groups
of each extremity, with mean MRC-scores of <4 (antigrav-
ity strength) indicating ICUAW. It has shown good
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syndrome [87]. Values of <11-kg force for men and <7-kg
force for women at dominant-hand dynamometry have also
been described to identify ICU-acquired weakness in
previously healthy individuals [88]. Nevertheless—and in
spite of daily wake up calls, both approaches share one
major limitation—the requirement for patient cooperation
and consciousness, which may be inadequate due to
deliriumresultingfromsedationand/orsepticencephalopathy.
Electrophysiologic testing offers an additional approach to
estimate neuromuscular dysfunction in unconscious patients
incapable of voluntary contraction. Moreover, electrophysio-
logic testing after direct muscle stimulation can be conducted
inunconscious/sedatedpatientsandhasbeenshowntopredict
ICUAW with high sensitivity and specificity in mechanically
ventilated,sedatedpatientsanddifferentiatesbetweenprimary
nerve or muscle dysfunction [89]. However, as it requires
some expertise and certain devices to perform these measure-
ments, use of this technique is currently restricted to larger
facilities or experts.
3.3 Risk factors involved in ICUAW
While the exact molecular mechanisms contributing to
ICUAW remain to be elucidated, five central risk factors of
ICUAW have been repeatedly reported [34]. As there are
currently no specific therapies, minimising exposure to
these risk factors is crucial in order to prevent this
devastating neuromuscular complication. Possibly the most
important risk factor complex comprises conditions leading
to multiple organ failure, particularly severe sepsis and
septic shock. Some authors actually consider ICUAW an
additional organ failure following severe sepsis and septic
shock. The other four risk factors of ICUAW involve
muscle inactivity, disturbances of glucose metabolism
resultinginhyperglycaemia,administrationofcorticosteroids,
and use of neuromuscular blocking agents (Fig. 1).
3.4 Implications for minimising risk factor exposure
and treatment options
3.4.1 Sepsis
In addition to the optimum realisation of early goal-directed
sepsis therapy [13], there are a number of hypothetical
approaches targeting inflammation-mediated multiple organ
failure, such as reducing levels of distinct cytokines by
extracorporeal measures [31, 90–94]o rr e s t o r i n gt h ei m m u -
nological equilibrium by pharmaceutical immunomodulation
[28–30]. However, the current literature on ICUAW has not
considered sepsis-induced affections in cellular immunity to
participate directly in the induction of neuromuscular
dysfunction.
3.4.2 Immobilisation
Schweickert and colleagues [95] recently reported that
patients undergoing an ambitious protocol of early and
determined mobilisation were more frequently able to get
out of bed, stand and occasionally walk with assistance
during mechanical ventilation whereas standard regimens
of physical therapy led to longer impairment of functional
status and recovery time. Besides, early mobilisation was
associated with a shorter duration of delirium. It is possible,
that additional electrical muscle stimulation (EMS) assists
in preventing ICUAW, since studies indicate that EMS
partially prevents muscle atrophy in critically ill patients
[96] and mitigates increased proteasome activation besides
stimulating insulin like growth factor in patients after major
abdominal surgery [97]. Preliminary data of our ongoing
trial on ICUAW prevention by daily EMS supports this, as
it indicates improvement of muscle membrane excitability
in critically ill patients at high risk for ICUAW (unpub-
lished data). Importantly, EMS can be initiated immediately
after ICU admission and could facilitate faster mobilisation
progress. Implementation of protocol-based sedation and
weaning measures may further reduce the incidence of
ICUAW and weanig failure (Fig. 2).
3.4.3 Intensive insulin therapy
Increased serum glucose levels are typical findings in
patients with severe sepsis and septic shock. Studies from
van den Berghe and colleages reported that intensive
insulin therapy (IIT) was associated with a lower incidence
of ICUAW [98, 99]. However, recent data from the NICE-
SUGAR trial demonstrates that 90-day mortality rate is
significantly lower in critically ill patients with liberal
glycemic control (serum glucose ≤180 mg/dl) vs. those
patients receiving IIT, the risk of severe hypoglycemia
being significantly higher in the IIT group [19, 20].
Although tight glycemic control as a general approach in
ICU patients is currently controversial, it seems reasonable
that protocol-based glycemic control targeting prevention of
excessive blood glucose levels and variability help reduce
the incidence of ICUAW.
3.4.4 Glucocorticoid exposure
Although de Jonghe et al. identified corticosteroid admin-
istration as the strongest predictor for ICU-acquired
weakness [100], data from a recent meta-analysis does not
indicate a clear relationship between systemic levels of
corticosteroids and myotoxic effects in patients with sepsis
[81]. Development of steroid induced myopathy [101, 102]
may be dependent on steroid doses applied, which is in line
with findings from our group, that do not indicate an
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and impaired muscle membrane excitability—one of the
key features in ICUAW patients with predominant myopathy
[103]. Yet, as this observation has to be confirmed by other
groups, strict indication is still warranted considering low-
dose hydrocortisone administration.
3.4.5 Neuromuscular blockers
Treatment with neuromuscular blocking agents has been
reported to contribute to ICUAW development. Initial
reports stated that vecuronium and pancuronium may be
particularly harmful in regard to critical illness neuromus-
cular abnormalities [104]. It remains unclear, however,
whether this is simply attributable to the rather widespread
use of these substances at that time. Importantly, renal
function must be taken into account, as some neuromuscu-
lar blocking agents undergo excretion via the kidneys. As
firm conclusions regarding specific deleterious effects of
neuromuscular blockers are precluded, cautious use is still
warranted [34].
3.5 Subclassification of ICUAW
Depending on electrophysiologic or histological documen-
tation of neuropathy and/or myopathy, ICUAW can be
further subclassified as critical illness myopathy (CIM),
critical illness polyneuropathy (CIP), or critical illness
myoneuropathy (CIMN), which is more frequent than
previously thought and applies to ICUAW patients with
coinciding neuropathy and myopathy [35]. Myopathy is
likely to present the predominant feature of ICUAW and
has been shown to precede neuropathy in patients with
CIMN [89]. Yet, as both histology and electrophysiology
are currently not obtained during clinical routine, subclas-
sification of ICUAW may seem of less importance to
clinicians dealing with this complication. We just recently
demonstrated that myopathy occurs earlier and more
frequent, whereas additional polyneuropathy develops later
and less frequent. By showing that additional polyneurop-
athy was associated with longer ICU length of stay, we
suggest that differential diagnosis of ICUAW becomes
more important to clinicians [105].
Fig. 2 Suggested beneficial effects of electrical muscle stimulation
(EMS) with regard to muscle hypertrophy, atrophy, aerobic capacity,
membrane excitability and membrane translocation of GLUT4. EMS
may preserve membrane excitability. Membrane translocation of
GLUT4 is regulated by IGF-1, AMPK, PGC-1α and its downstream
targets, which may all be affected by EMS. Atrophy gene expression
(MuRF-1, atrogin-1) increases upon desphosphorylation of FoxO3
trancription factors, which is inhibited by downstream insulin
signalling. EMS electrical muscle stimulation, IGF-1 insulin growth
factor-1, GLUT4 glucose transporter 4, IRS-1 insulin receptor
substrate 1, AMPK AMP-activated protein kinase, PI3K phopshoino-
sitide 3-kinase, PPAR peroxisome proliferator-activated receptor,
PGC-1α PPAR-γ coactivator 1α, pAKT phosphorylated Akt protein
kinase B, mTOR mammalian target of rapamycin, FoxO3 forkhead
box O3, MuRF muscle-specific ring finger protein
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Three characteristics are commonly described in patients with
CIM or CIMN [106–108]:
– Selective thick filament loss
– Predominant type II muscle fibre atrophy (Fig. 3)
– Muscle membrane inexcitability
Unspecific but predominant type II (fast twitch) muscle
fibre atrophy has been repeatedly described within muscle
tissue from CIM/CIMN biopsies [35]. Selective but patchy
loss of myosin filaments can be visualised by electron
microscopy and is considered a hallmark of CIM, explaining
its additional terminology of thick filament myopathy [35].
In contrast to these morphologic alterations, non-excitable
muscle membrane is detected by electrophysiologic testing
[43, 108, 109] and has been shown to predict ICUAW in
mechanically ventilated, sedated patients with high sensitiv-
ity and specificity [89]. All three characteristics may result in
different mechanisms leading to ICUAW, as loss of muscle
mass (atrophy) correlates with decreased maximum force,
thick filament loss represents an additional reduction of force
generating capacity by additional myofilament dysfunction,
and non-excitable muscle membrane may be considered as
an incapability of the muscle to generate contraction-
preceding action potentials. Less frequently described histo-
logical signs of CIM/CIMN include acute necrosis [110,
111], regeneration [112]a sw e l la sl o s so fm y o f i b r i l l a r
ATPase staining [113], the latter affecting both type I and II
muscle fibres.
3.7 Suggested subcellular abnormalities in sepsis-induced
myopathy
A number of subcellular sites involved in excitation
contraction coupling may be affected in sepsis-induced
myopathy [36]. These include the sarcolemma, the sarco-
plasmatic reticulum, the contractile apparatus and the
mitochondria. As described above, one of the key features
of CIM/CIMN is that skeletal muscle becomes electrically
inexcitable, which has led to the concept that CIM/CIMN
could represent an acquired channelopathy involving
dysregulation of sodium channels located at the sarcolem-
ma. Experimental studies describe sarcolemmal injuries in
diaphragm and limb muscle that were in part associated
with excessive nitric oxide generation [114–116]. Altered
calcium homeostasis has been observed in a number of
studies on skeletal muscle during sepsis with calcium level
increases in some subcellular compartments and decreases
in others [36]. Contractile protein dysfunction resulting in
reduced force pCa relationship has been reported in
diaphragm and limb muscle in a number of sepsis models
[117–120]. It is likely that free radical generation is
involved in this mechanism, as either a superoxide
scavenger or NO synthesis inhibitor significantly attenuated
reduced endotoxin-induced force pCa relationships. TNF-α
has been linked to decreases in titanic force generation due
to changes in myofilament function, as well [121, 122]. A
considerable amount of data indicates that sepsis also causes
profound alterations in respiratory muscle mitochondrial
function [36]. Limb muscle biopsies from septic patients
show decreased mitochondrial content and lower concen-
trations of energy rich phosphates [123].
4 Conclusions and outlook
In conclusion, sepsis and systemic inflammation may lead to
multiple organ failure, which isassociated withloss ofmuscle
mass and/or onset of ICUAW. ICUAW presents a significant
clinical problem and is thought to affect up to 50% of all ICU
patients. As an increasing amount of patients survives sepsis,
long-term complications of critical care are likely to gain in
significance. Short term complications of ICUAW include
Fig. 3 Muscle histologies (vastus lateralis muscle) from an ICU
patient with critical illness myopathy (subclassification of ICUAW)
and an ICU patient without this complication, referred to as ICU
control. ATPase/Toludine blue staining differentiates type I, IIa and IIb
muscle fibres as indicated
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tion of rehabilitation measures, failure in weaning from
mechanical ventilation and others. Currently, there is no
causal therapy of ICUAW and measures are restricted to
minimising risk factor exposure. Risk factors besides multiple
organfailure—whichismostlikelyduetosepsisandsystemic
inflammation—include excessive blood glucose levels,
immobilisation, exposure to neuromuscular blockers and
corticosteroid application. Therefore, measures such as
identification of risk patients, avoidance of unnecessarily
deep sedation, promotion of early mobilisation and EMS,
prevention of excessive blood glucose levels, rational admin-
istration of glucocorticoids and/or neuromuscular blockers as
well as early goal-directed therapy of sepsis seem to reduce
the severityand incidence ofICUAW. Nutritional approaches,
immunomodulatory interventions, antioxidant treatment or
others might furthermore lower the incidence of muscle
wasting and ICUAW in critically ill patients.
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